Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-18 06:19 am Purchase |
2025-02-11 | 13G | Lixte Biotechnology Holdings, Inc. LIXT |
Mitchell P. Kopin | 138,763 4.990% |
138,763 (New Position) |
Filing History |
| 2025-02-11 4:53 pm Purchase |
2025-02-05 | 13G | 60 Degrees Pharmaceuticals, Inc. SXTP |
Mitchell P. Kopin | 77,358 4.990% |
20,448 (+35.93%) |
Filing History |
| 2025-02-11 4:51 pm Purchase |
2025-02-05 | 13G | Mustang Bio, Inc. MBIO |
Mitchell P. Kopin | 186,552 9.990% |
186,552 (New Position) |
Filing History |
| 2025-02-05 5:15 pm Purchase |
2025-01-30 | 13G | Enveric Biosciences, Inc. ENVB |
Mitchell P. Kopin | 103,951 4.990% |
103,951 (New Position) |
Filing History |
| 2025-02-05 5:13 pm Purchase |
2025-01-30 | 13G | SaverOne 2014 Ltd SVRE |
Mitchell P. Kopin | 909,218 4.990% |
909,218 (New Position) |
Filing History |
| 2025-02-03 4:05 pm Purchase |
2025-01-28 | 13G | 60 Degrees Pharmaceuticals, Inc. SXTP |
Mitchell P. Kopin | 56,910 4.990% |
56,910 (New Position) |
Filing History |
| 2025-01-28 5:25 pm Purchase |
2025-01-23 | 13G | Dermata Therapeutics, Inc. DRMA |
Mitchell P. Kopin | 262,468 6.700% |
262,468 (New Position) |
Filing History |
| 2025-01-27 06:14 am Purchase |
2025-01-21 | 13G | Color Star Technology Co., Ltd. ADD |
Mitchell P. Kopin | 504,488 9.990% |
504,488 (New Position) |
Filing History |
| 2025-01-21 5:49 pm Purchase |
2025-01-15 | 13G | Silexion Therapeutics LTD SLXN |
Mitchell P. Kopin | 209,827 4.990% |
209,827 (New Position) |
Filing History |
| 2025-01-17 4:44 pm Purchase |
2025-01-13 | 13G | Phio Pharmaceuticals Corp. PHIO |
Mitchell P. Kopin | 530,171 9.990% |
439,184 (+482.69%) |
Filing History |
| 2025-01-16 6:34 pm Purchase |
2025-01-12 | 13G | NAYA Biosciences, Inc. NAYA |
Mitchell P. Kopin | 42,040 6.900% |
26,706 (+174.17%) |
Filing History |
| 2025-01-15 4:03 pm Purchase |
2024-12-31 | 13G | PharmaCyte Biotech, Inc. PMCB |
Mitchell P. Kopin | 714,844 9.990% |
714,844 (New Position) |
Filing History |
| 2025-01-14 5:49 pm Purchase |
2025-01-07 | 13G | ReWalk Robotics Ltd. LFWD |
Mitchell P. Kopin | 553,821 4.990% |
213,067 (+62.53%) |
Filing History |
| 2025-01-14 5:45 pm Unchanged |
2025-01-08 | 13G | DatChat, Inc. DATS |
Mitchell P. Kopin | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2025-01-10 6:53 pm Purchase |
2025-01-06 | 13G | Microbot Medical Inc. MBOT |
Mitchell P. Kopin | 2,672,084 8.800% |
2,672,084 (New Position) |
Filing History |
| 2025-01-10 6:51 pm Purchase |
2025-01-06 | 13G | BioLineRx Ltd. BLRX |
Mitchell P. Kopin | 2,555,903 4.990% |
2,077,581 (+434.35%) |
Filing History |
| 2025-01-03 8:08 pm Purchase |
2024-12-27 | 13G | 180 Life Sciences Corp. ATNF |
Mitchell P. Kopin | 165,293 4.990% |
165,293 (New Position) |
Filing History |
| 2025-01-03 8:04 pm Purchase |
2024-12-26 | 13G | Gaxos.ai Inc. GXAI |
Mitchell P. Kopin | 363,625 4.990% |
70,728 (+24.15%) |
Filing History |
| 2024-12-30 5:39 pm Purchase |
2024-12-22 | 13G | Vivos Therapeutics, Inc. VVOS |
Mitchell P. Kopin | 297,315 4.990% |
297,315 (New Position) |
Filing History |
| 2024-12-27 5:05 pm Purchase |
2024-12-19 | 13G | Phio Pharmaceuticals Corp. PHIO |
Mitchell P. Kopin | 90,987 4.990% |
45,782 (+101.28%) |
Filing History |